The Employers’ Guide to GLP-1s

  • White Paper
  • Noom Weight
  • 7 min read


As the demand for GLP-1s continues to surge, it’s no surprise they’re now among the top-cost drugs for employers. In this white paper, learn everything you need to know about GLP-1s to guide your obesity care strategy.

Ozempic and Mounjaro side effects

Breakthrough anti-obesity medications called GLP-1s have revolutionized the treatment landscape for obesity. While these medications have proven effective, they can be costly. If just half of those eligible sought GLP-1s for weight loss, prescription costs could increase by more than $840 per member per year across the entire population. Now more than ever before, employers need a proactive GLP-1 strategy to eliminate unnecessary spend, while optimizing health outcomes.  

In this white paper, you’ll discover:

  • The latest evidence behind GLP-1s
  • Why GLP-1s may not be for everyone
  • The importance of a multidisciplinary, stepped care approach to sustain long-term health outcomes and control costs

Download the White Paper

By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.

Bring Noom to
your organization

Give your workforce a preview of what’s possible
for their physical and mental health.